Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Is proteomics of value in cardiovascular risk assessment?

Arnold, Nataliea,b; Koenig, Wolfgangc,d,e

doi: 10.1097/MOL.0000000000000639
THERAPY AND CLINICAL TRIALS: Edited by Erik S.G. Stroes and Gerald F. Watts
Buy
SDC

Purpose of review To briefly summarize recently published evidence in the field of cardiovascular proteomics, focusing on its ability to improve cardiovascular risk stratification and critically discussing still open and burning issues and future perspectives of proteomics research.

Recent findings Several epidemiological studies have demonstrated an improvement in cardiovascular risk prediction beyond traditional risk factors by adding novel biomarkers, identified by both discovery and targeted proteomics. However, only a moderate improvement in risk discrimination over clinical variables was observed. Moreover, despite different outcomes there was also a strong overlap of identified candidates, with several of them being already well established cardiovascular risk markers such as growth differentiation factor 15, natriuretic peptides, C-reactive protein, interleukins, and metalloproteases.

Summary Although proteomics plays a crucial role in biomarker discovery, the modest discriminative ability of this technique raises the possibility that there are still hidden mechanisms in protein regulatory networks, which urgently need to be evaluated to improve a cardiovascular risk assessment to a clinically significant extent.

aPreventive Cardiology and Preventive Medicine, Centre for Cardiology, University Medical Centre of the Johannes Gutenberg-University Mainz

bDZHK (German Center for Cardiovascular Research), partner site Rhine-Main, Mainz

cDeutsches Herzzentrum München, Technische Universität München, München

dDZHK (German Centre for Cardiovascular Research), partner site Munich Heart, Alliance, Germany

eInstitute of Epidemiology and Medical Biometry, University of Ulm, Ulm, Germany

Correspondence to Wolfgang Koenig, MD, PhD, FRCP, FACC, FAHA, FESC, Deutsches Herzzentrum München, Technische Universität München, Lazarettstr. 36, 80636 München, Germany. Tel: +49 89 1218 4073; fax: +49 89 1218 2023; e-mail: koenig@dhm.mhn.de

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Website (www.co-lipidology.com).

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.